| Dr Joseph Leonard Decarlo, MD | |
|
700 Olympic Plaza Cir, Ste 700, Tyler, TX 75701-1951 | |
| (903) 262-3900 | |
| (903) 262-3993 |
| Full Name | Dr Joseph Leonard Decarlo |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 38 Years |
| Location | 700 Olympic Plaza Cir, Tyler, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013954809 | NPI | - | NPPES |
| 129781401 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | J0472 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ut Health East Texas Tyler Regional Hospital | Tyler, TX | Hospital |
| Christus Mother Frances Hospital | Tyler, TX | Hospital |
| Ut Health East Texas Jacksonville Hospital | Jacksonville, TX | Hospital |
| Ut Health East Texas Henderson Hospital | Henderson, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Etmc Physician Group, Inc. | 4486915600 | 276 |
News Archive
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.
Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.
Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.
› Verified 3 days ago
| Entity Name | Etmc Physician Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609382662 PECOS PAC ID: 4486915600 Enrollment ID: O20180305002106 |
News Archive
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.
Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.
Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Leonard Decarlo, MD 700 Olympic Plaza Cir, Ste 700, Tyler, TX 75701-1951 Ph: (903) 262-3900 | Dr Joseph Leonard Decarlo, MD 700 Olympic Plaza Cir, Ste 700, Tyler, TX 75701-1951 Ph: (903) 262-3900 |
News Archive
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections.
Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.
Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.
› Verified 3 days ago
Steven Lomax, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 700 Olympic Plaza Cir Ste 700, Tyler, TX 75701 Phone: 903-262-3900 | |
Dr. Charles T Dickson, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 700 Olympic Plaza Cir, Ste 700, Tyler, TX 75701 Phone: 903-262-3900 Fax: 903-262-3993 | |
Dr. Clark Alexander Wilson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 700 Olympic Plaza Cir Ste 700, Tyler, TX 75701 Phone: 032-623-9009 Fax: 903-262-3993 | |
William Bruce Harrell, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 910 E Houston St, Ste 600, Tyler, TX 75702 Phone: 903-526-2644 | |
Dr. Robert Clay Williams, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 700 Olympic Plaza Cir, Ste 700, Tyler, TX 75701 Phone: 903-262-3900 Fax: 903-262-3993 | |
David A Peifer, DO Urology Medicare: Medicare Enrolled Practice Location: 910 E Houston St Ste 600, Tyler, TX 75702 Phone: 903-526-2644 |